



# **PALM-COEIN:** **Your AUB** **Counseling** **Guide**

# 10 million+

## Treat the cause, not the symptom

In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB<sup>1</sup>

Diagnosis	Cause
	<b>Structural</b>
AUB-P	Polyps
AUB-A	Adenomyosis
AUB-L	Leiomyoma
AUB-M	Malignancy/Hyperplasia
	<b>Non Structural</b>
AUB-C	Coagulopathy
AUB-O	Ovulatory Dysfunction
AUB-E	Endometrial Disorders
AUB-I	Iatrogenic
AUB-N	Not Classified



## AUB-P Polyps

### Symptoms

- Menorrhagia
- Infertility
- Post menopausal bleeding<sup>2</sup>

### Medical relevance

- May be asymptomatic and/or may contribute to AUB. Potential for malignancy and/or infertility.

### Some treatment options include:

Medical therapy, NovaSure® endometrial ablation, MyoSure® tissue removal, curettage<sup>3</sup>

# AUB-P Polyps

## IMAGING AND DIAGNOSIS

### **Sonohysterography (SIS)**

- Substantial evidence exists to indicate that sonohysterography is superior to transvaginal ultrasonography in the detection of intracavitary lesions, such as polyps and submucosal leiomyomas.<sup>4</sup>
- SIS provides better information on the general size and location of cavitory abnormalities in comparison to TVUS.<sup>5</sup>

### **Hysteroscopy**

- Hysteroscopy offers direct visualization of the uterine cavity including exact information on specific size and location.
- Hysteroscopy allows the ability to see and treat intracavitary pathology simultaneously.<sup>6</sup>



# AUB-A Adenomyosis

## Symptoms

- AUB
- Dysmenorrhea
- Enlarged uterus<sup>3</sup>

## Medical relevance

- Endometrial tissue within the myometrium.  
Often found by MRI, the relationship between Adenomyosis and AUB is not well understood.

## Some treatment options include:

NSAIDs, hormone therapy, uterine artery embolization, NovaSure® endometrial ablation, hysterectomy<sup>3</sup>

# AUB-A Adenomyosis

## RADIOLOGIC FINDINGS

- Localized thickening of junctional zone
- Poorly defined endometrial borders
- High signal intensity spots MRI/TVUS<sup>1</sup>

## IMAGING AND DIAGNOSIS

### Transvaginal ultrasound

- Transvaginal ultrasonography may perform less well in the presence of an enlarged uterus or with coexisting myomas.<sup>4</sup>

### MRI

- Some experts recommend transvaginal ultrasonography as the initial screening test for AUB and MRI as a secondline test when the diagnosis is inconclusive, when further delineation would affect patient management, or when coexisting uterine myomas are suspected.<sup>4</sup>



## AUB-L Leiomyoma

### Symptoms

- UB
- Pelvic pressure and/or heaviness
- Urinary frequency
- Dysmenorrhea
- Abdominal enlargement
- Pregnancy loss
- Infertility<sup>7</sup>

### Risk factors

- Nullparity
- Obesity
- Family history
- Hypertension
- African-American<sup>7</sup>

### Some treatment options include:

Hormone therapy, MyoSure<sup>®</sup> tissue removal, uterine artery embolization, myomectomy, hysterectomy<sup>8</sup>

# AUB-L Leiomyoma



## IMAGING AND DIAGNOSIS

### Transvaginal ultrasound

- The primary imaging test of the uterus for the evaluation of AUB is transvaginal ultrasonography.<sup>4</sup>

### Sonohysterography (SIS)

- If TVUS images are not adequate or further evaluation of the cavity is necessary, then sonohysterography (SIS) or hysteroscopy (preferably in the office setting) is recommended.<sup>6</sup>





# AUB-M Malignancy/Hyperplasia

## Risk factors

- Obesity
- Prolonged anovulation
- Post menopausal estrogen replacement therapy
- Tamoxifen
- Family history
- Hypertension
- Diabetes<sup>s</sup>

## Some treatment options include:

Hormone therapy, radiation therapy, chemotherapy, hysterectomy<sup>s</sup>

# AUB-M

## Malignancy/Hyperplasia

### Diagnostic approach

- Endometrial tissue sampling should be performed in patients with AUB who are older than 45 years as a first-line test.<sup>8</sup>
- Endometrial sampling also should be performed in patients younger than 45 years with a history of unopposed estrogen exposure (such as seen in obesity or PCOS), failed medical management, and persistent AUB.<sup>8</sup>
- Endometrial biopsy has high overall accuracy in diagnosing endometrial cancer when an adequate specimen is obtained and when the endometrial process is global.<sup>8</sup>

# AUB-C Coagulopathy

## INHERITED (Von Willebrand)

### Examples

- Von Willebrand disease (13%)
- Carrier states for factor deficiencies
- Idiopathic thrombocytopenia purpura (platelet # abnormalities)
- Platelet dysfunctions (platelet function abnormalities)
- Leukemia
- Liver dysfunction<sup>9</sup>

### Diagnostic approach

- Initial tests should include a CBC with platelets, prothrombin time, and partial thromboplastin time (fibrinogen or thrombin time are optional).
- Depending on the results of the initial tests, specific tests for von Willebrand disease or other coagulopathies may be indicated.<sup>3</sup>

### Some treatment options include:

Therapeutic environment, gonadal steroid agents, antifibrinolytic therapy, NovaSure® endometrial ablation<sup>3</sup>

# AUB-O

## Ovulatory Disorders

**PREVIOUSLY CALLED “DUB” ACQUIRED<sup>3</sup>**

### **Symptoms**

- Irregular bleeding patterns

### **Possible causes**

- Hypothalamic dysfunction (stress)
- Polycystic ovary syndrome (PCOS)
- Eating disorders<sup>3</sup>

### **Diagnostic approach**

- Laboratory testing (pregnancy test, complete blood count, measurement of thyroid-stimulating hormone (TSH) levels and cervical cancer screening). Testing for Chlamydia trachomatis should be considered.<sup>4</sup>

### **Some treatment options include:**

Medical therapy, gonadal steroids, NovaSure® endometrial ablation, IUD, hysterectomy<sup>3</sup>

# AUB-E

## Endometrial Disorders

### REQUIRES UNDERSTANDING OF STRUCTURED HISTORY AND EXCLUSION

#### Definition

- Ovulatory cycle with no structural or systematic abnormalities

#### Possible causes

- Impaired vasoconstriction (ratio of  $\text{PGF2}\alpha$ :prostacyclin)
- Enhanced fibrinolysis
- Localized hemostatic disorder

#### Diagnostic approach

- No commercial testing available<sup>9</sup>

#### Some treatment options include:

Medical therapy, gonadal steroids, NovaSure<sup>®</sup> endometrial ablation, IUD, hysterectomy<sup>3</sup>

# AUB-I Iatrogenic

## REQUIRES UNDERSTANDING OF STRUCTURED HISTORY AND EXCLUSION

### Examples

- Warfarin
- Heparin
- IUD
- Oral contraceptive

### Possible causes

- BTB a result of poor patient compliance
- Bleeding induced by gonadal steroidal therapy

### Diagnostic approach

- Targeted medical history<sup>8</sup>

### Some treatment options include:

Estrogen/Progestin contraceptive agents,  
therapeutic agents<sup>3</sup>

# AUB-N Not Classified

## REQUIRES UNDERSTANDING OF STRUCTURED HISTORY AND EXCLUSION

### Examples

- Ateriovenous malformations
- Associations with some systematic diseases
- Endometritis

### Diagnostic approach

- Doppler scanning
- Biopsy and cultures<sup>3,8</sup>

# References

1. "Diagnosis of abnormal uterine bleeding in reproductive-aged women." Practice Bulletin No. 128 197-203. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120; 197-206.
2. Salim et al. Diagnosis and Management of Endometrial Polyps: A Critical Review of the Literature. J Minim Invasive Gynecol. 2011 Jul 21.
3. Munro MG *Abnormal Uterine Bleeding*. Cambridge, 2010 Cambridge University Press. Chapter 9-11. Pages 89-116.
4. Kelekci S, Kaya E, Alan M, Alan Y, Bilge U, Mollamahmutoglu L. Comparison of transvaginal sonography, saline infusion sonography, and office hysteroscopy in reproductive-aged women with or without abnormal uterine bleeding. Fertil Steril 2005;84:682-6. (Level II-3).
5. Schwarzler P, Concin H, Bosch H, Berlinger A, Wohlgemant K, Collins WP, et al. An evaluation of sonohysterography and diagnostic hysteroscopy for the assessment of intrauterine pathology. Ultrasound Obstet Gynecol 1998;11:337- 42. 6.
6. Hysteroscopy. Technology Assessment No. 7. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;117:1486-91.
7. Baird DD, et al. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. American Journal of Obstetrics and Gynecology. 2003;188:100.
8. Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. 204 Practice Bulletin *Abnormal Uterine Bleeding OBSTETRICS & GYNECOLOGY* age. FIGO Working Group on Menstrual Disorders. Int J Gynaecol Obstet 2011;113:3-
9. Lukes MD, et al. *Fertility and Sterility* "Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact." 2005 Nov; 14 (5) 1338-1344.

**[hologic.com](http://hologic.com) | [info@hologic.com](mailto:info@hologic.com) | +1.781.999.7300**